Key facts
- NovAliX’s last known valuation is $114.0M.
- It has raised $24.0M; the latest was Later Stage VC ($21.7M) in Aug 2024.
- Notable investors include Bruker.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for NovAliX
- ·The full record, as it builds
Funding rounds
No funding rounds for NovAliX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NovAliX
Operator of a drug-based research center, intended to focus on drug discovery and pharmaceutical development. The company's center offers clients original collaborative models and extensive services within the framework of research programs dedicated to drug discovery, enabling clients to have a unique combination of screening, medicinal chemistry, and structural biology to discover effective drugs.
- Sector
- Healthcare
- HQ
- Strasbourg, France
- Founded
- 2002
- Employees
- 367
- Website
- novalix.com/
- Ownership
- Privately Held (backing)
NovAliX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NovAliX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NovAliX in its N-PORT filings yet. We sweep new filings monthly.